Continuous Glucose Monitoring and Time in Range: Association with Adverse Outcomes among People with Type 2 or Gestational Diabetes Mellitus
Authors:
- 1 March 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 41 (S 01) , e1370-e1377
Abstract
Objective Continuous glucose monitoring (CGM) has become available for women with type 2 diabetes mellitus (T2DM) or gestational diabetes mellitus (GDM) during pregnancy. The recommended time in range (TIR, blood glucose 70–140 mg/dL) and its correlation with adverse pregnancy outcomes in this group is unknown. Our aim was to compare maternal and neonatal outcomes in pregnant people with T2DM or GDM with average CGM TIR values >70 versus ≤70%. Study Design We conducted a retrospective cohort study of all individuals using CGM during pregnancy from January 2017 to June 2022. Individuals with type 1 diabetes mellitus, or those missing CGM or delivery data were excluded. Primary composite neonatal outcome included any of the following: large for gestational age, NICU admission, need for intravenous glucose, respiratory support, or neonatal death. Secondary outcomes included other maternal and neonatal outcomes. Regression models were used to estimate adjusted odds ratio (aOR) and 95% confidence interval (CI). Results During the study period, 141 individuals with diabetes utilized CGM during pregnancy, with 65 (46%) meeting inclusion criteria. Of the study population, 28 (43%) had TIR ≤70% and 37 (57%) had TIR > 70%. Compared with those with TIR > 70%, the primary composite outcome occurred more frequently in neonates of individuals TIR ≤70% (71.4 vs. 37.8%, aOR: 4.8, 95% CI: 1.6, 15.7). Furthermore, individuals with TIR ≤70% were more likely to have hypertensive disorders (42.9 vs. 16.2%, OR: 3.9, 95% CI: 1.3, 13.0), preterm delivery (54 vs. 27%, OR: 3.1, 95% CI: 1.1, 9.1), and cesarean delivery (96.4 vs. 51.4%, OR: 4.6, 95% CI: 2.2, 15.1) compared with those with TIR >70%. Conclusion Among people with T2DM or GDM who utilized CGM during pregnancy, 4 out 10 individuals had TIR ≤70% and, compared with those with TIR > 70%, they had a higher likelihood of adverse neonatal and maternal outcomes. Key PointsKeywords
This publication has 30 references indexed in Scilit:
- A Revised Birth Weight Reference for the United StatesObstetrics & Gynecology, 2014
- Real‐time continuous glucose monitoring as a tool to prevent severe hypoglycaemia in selected pregnant women with Type 1 diabetes – an observational studyDiabetic Medicine, 2014
- Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention TrialDiabetes Care, 2011
- Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trialBMJ, 2008
- Managing Preexisting Diabetes for PregnancyDiabetes Care, 2008
- Changes in the Glycemic Profiles of Women With Type 1 and Type 2 Diabetes During PregnancyDiabetes Care, 2007
- Introductory Experience with the Continuous Glucose Monitoring System (CGMS®; Medtronic Minimed®) in Detecting Hyperglycemia by Comparing the Self-Monitoring of Blood Glucose (SMBG) in Non-Pregnant Women and in Pregnant Women with Impaired Glucose Tolerance and Gestational DiabetesExperimental and Clinical Endocrinology & Diabetes, 2004
- Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitusThe Journal of Maternal-Fetal & Neonatal Medicine, 2003
- The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) StudyInternational Journal of Gynecology & Obstetrics, 2002
- Pregnancy outcomes in the Diabetes Control and Complications TrialAmerican Journal of Obstetrics and Gynecology, 1996